Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences
Open Access
- 21 January 2009
- journal article
- Published by H1 Connect in F1000 Medicine Reports
- Vol. 1 (2)
- https://doi.org/10.3410/m1-2
Abstract
Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequencesThis publication has 19 references indexed in Scilit:
- EAU Guidelines on Prostate CancerEuropean Urology, 2008
- Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancerCancer, 2008
- Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice GuidelineJournal of Clinical Oncology, 2007
- Cancer survivorship: resilience across the lifespan. Proceedings of the National Cancer Institute's and American Cancer Society's 2002 Cancer Survivorship Conference. June 2-4, 2002. Washington, DC, USA.2005
- Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancerBJU International, 2005
- Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancerUrology, 2002
- Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinomaCancer, 2002
- Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trialThe Lancet, 2002
- Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.2000
- Single-Therapy Androgen Suppression in Men with Advanced Prostate CancerAnnals of Internal Medicine, 2000